DMT

This article was originally published on Psychedelic Spotlight and appears here with permission. Scientists reveal new insights into how DMT affects various regions of the brain. The newly-released findings, featured in the journal Proceedings of the National Academy of Sciences, offer an...

A new study reveals the most advanced-to-date brain images of the effects of the psychedelic compound DMT. The trial, led by a group at Imperial College London, monitored brain activity of 20 healthy volunteers receiving either a 20mg DMT injection or a placebo through functional magnetic resonance...

This article was originally published on Psychedelic Spotlight and appears here with permission. DMT and psilocybin are both powerful elements of Mother Nature's alchemy, but do they offer an identical journey? Let’s explore to find out. Have you ever found yourself wondering about the...

Cybin Inc. (NYSE: CYBN) announced that it has received approval from an independent ethics committee in the Netherlands to begin the first in-human dosing of its proprietary deuterated N, N-dimethyltryptamine (DMT) molecule CYB004 through a protocol amendment to its ongoing CYB004-E...

This article by James Hallifax was originally published on Microdose and appears here with permission. 2022 was a milestone year for the psychedelic industry and its advocates, with massive victories in the realms of decriminalization and legalization, clinical trials, and business. And...

(Part three of a three-part series) See previous stories: EXCLUSIVE: Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans EXCLUSIVE: The Psychedelics Debate Is 'Raging' As Filament Debuts Ayahuasca Pill One of the concerns around what is commonly known as natural ...

Canadian clinical-stage psychedelics company Algernon Pharmaceuticals (OTCQB: AGNPF)’s newly created subsidiary Algernon NeuroScience (AGN Neuro) has dosed the first subject in its Phase 1 clinical study of proprietary IV formulation of DMT, AP-188. The trial is being conducted at the Centre...

In Australia, a new study conducted by the University of Melbourne analyzed data from an Online Global Ayahuasca Survey conducted between 2017 and 2019 that showed 10,836 people over the age of 18 had used ayahuasca at least once. “With the expansion of ayahuasca ceremonies from their...

Small Pharma Inc. (OTCQB: DMTTF), a biotech company that develops short-acting psychedelic-assisted therapies for depression, received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Research Ethics Committee to begin a Phase 1 clinical study...

Biopharma company Algernon Pharmaceuticals Inc's (OTC: AGNPF) recently announced plan for a Phase 1 clinical study on DMT for human stroke has just received approval from the Stichting Beoordeling Ethiek Biomedisch Onderzoek (BEBO), an independent Medical Research Ethics Committee....

PsyBio Therapeutics (TSXV: PSYB) (OTCQB: PSYBF), a biotech developing medicines based on naturally-occurring psychedelic substances, and mushroom producer Red Light Holland Corp. (OTC Pink: TRUFF) announced the release of financial results and operational highlights. The First Six Months...

This article was originally published on Microdose and appears here with permission. Psychedelic research is becoming the future of mental health, with more and more studies showing their effectiveness in the treatment of mood disorders. Psychedelics like psilocybin, DMT, and ibogaine...

This article was originally published on Psychedelic Spotlight and appears here with permission. DMT is a popular hallucinogen being studied for its therapeutic potential, but is smoking DMT safe? Here’s everything you need to know. DMT is widely reported to be the most powerful hallucinogen...

This article was originally published on Psychedelic Spotlight and appears here with permission. DMT is a powerful hallucinogen famous for producing experiences of encounters with entities, but how many people actually see them? If you take a trip to the Amazonian basin, you can find the perennial...

This article by Elisabetta Fato was originally published on Microdose and appears here with permission. Preliminary results from Phase 1 DMT clinical trial for depression support the safety and tolerability of the compound. With a world-first Phase 2 trial getting underway, we are on the cusp...